Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BRKR Stock Forecast 2026-2027
$54.23
Current Price
$8.26B
Market Cap
Buy 8
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to BRKR Price Targets
+27.2%
To High Target of $69.00
-2.3%
To Median Target of $53.00
-35.5%
To Low Target of $35.00
BRKR Price Momentum
-3.8%
1 Week Change
+23.7%
1 Month Change
+41.6%
1 Year Change
+15.1%
Year-to-Date Change
-16.0%
From 52W High of $64.54
+90.1%
From 52W Low of $28.53
📊 TOP ANALYST CALLS
Did BRKR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bruker is one of their latest high-conviction picks.
Latest BRKR Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, BRKR has a bullish consensus with a median price target of $53.00 (ranging from $35.00 to $69.00). The overall analyst rating is Buy (7.8/10). Currently trading at $54.23, the median forecast implies a -2.3% downside. This outlook is supported by 8 Buy, 4 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BRKR Analyst Ratings
8
Buy
4
Hold
1
Sell
BRKR Price Target Range
Low
$35.00
Average
$53.00
High
$69.00
Current: $54.23
Latest BRKR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BRKR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 8, 2026 | JP Morgan | Casey Woodring | Overweight | Maintains | $65.00 |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Peer Perform | Assumes | $N/A |
| May 7, 2026 | UBS | Neutral | Maintains | $N/A | |
| May 7, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| May 7, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| May 7, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 15, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 14, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 30, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Feb 13, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 13, 2026 | Goldman Sachs | Sell | Maintains | $N/A | |
| Feb 13, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Feb 13, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 26, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jan 16, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Jan 7, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Jan 5, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 15, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Dec 15, 2025 | Wells Fargo | Overweight | Maintains | $N/A |
Bruker Corporation (BRKR) Competitors
The following stocks are similar to Bruker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bruker Corporation (BRKR) Financial Data
Bruker Corporation has a market capitalization of $8.26B with a P/E ratio of 74.9x. The company generates $3.46B in trailing twelve-month revenue with a -0.3% profit margin.
Revenue growth is +2.7% quarter-over-quarter, while maintaining an operating margin of +6.2% and return on equity of -0.4%.
Valuation Metrics
Market Cap
$8.26B
Enterprise Value
$9.99B
P/E Ratio
74.9x
PEG Ratio
-0.9x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+2.7%
Gross Margin
+46.1%
Operating Margin
+6.2%
Net Margin
-0.3%
EPS Growth
-17.2%
Financial Health
Cash/Price Ratio
+1.6%
Current Ratio
1.6x
Debt/Equity
68.1x
ROE
-0.4%
ROA
+2.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bruker Corporation (BRKR) Business Model
About Bruker Corporation
What They Do
Develops high-performance scientific instruments and solutions.
Business Model
Bruker Corporation generates revenue through the sale of scientific instruments and analytical solutions, including nuclear magnetic resonance spectrometers, mass spectrometry platforms, and imaging systems. The company also offers software, applications support, training services, and maintenance agreements, creating a comprehensive suite of offerings for its customers in various sectors.
Additional Information
The company serves a diverse clientele, including pharmaceutical, biotechnology, and energy sectors, through its four main business segments. With a global presence and a strong focus on research and development, Bruker has established itself as a key player in advancing scientific research since its founding in 1960.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
11,085
CEO
Dr. Frank H. Laukien Ph.D.
Country
United States
IPO Year
2000
Website
www.bruker.comBruker Corporation (BRKR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
5 days ago
Quick Summary
Bruker Corporation (BRKR) presented at the Jefferies Global Healthcare Conference, discussing company developments and future outlook for investors.
Why It Matters
Bruker's presentation at a major healthcare conference signals potential growth opportunities and innovation, influencing investor sentiment and stock performance in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bruker (BRKR) reported earnings 30 days ago; investors should monitor upcoming developments for potential stock movement.
Why It Matters
Bruker's recent earnings report can signal its financial health and growth prospects, influencing stock performance and investor sentiment in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
9 days ago
Quick Summary
Bruker Corporation (Nasdaq: BRKR) is showcasing innovations in microbial identification and diagnostics at ASM Microbe 2026, highlighting advancements in sepsis and molecular testing capabilities.
Why It Matters
Bruker's advancements in microbial diagnostics could enhance market position and revenue growth, signaling potential for increased profitability and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bruker Corporation (Nasdaq: BRKR) launched the timsMRMS system for ultra-high-resolution MRMS at ASMS, enhancing oncology research by analyzing over 10,000 proteins in biopsies.
Why It Matters
Bruker's launch of the timsMRMS system enhances their position in precision oncology, potentially driving revenue growth and attracting investment through innovative technology in high-demand markets.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bruker Corporation (Nasdaq: BRKR) launched the timsMRMS system at ASMS, enhancing research in petroleomics and sustainable fuels through advanced mass spectrometry technology.
Why It Matters
Bruker's launch of the timsMRMS system enhances its competitive edge in energy research, potentially driving revenue growth and attracting investment in sustainable technologies.
Source: Business Wire
Market Sentiment:
Neutral
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
18 days ago
Quick Summary
Bruker Corporation has launched the BioSpec™ 18 Tesla preclinical MRI system at the Champalimaud Foundation in Lisbon, enhancing MRI capabilities for cancer and neuroscience research.
Why It Matters
The launch of Bruker's advanced MRI system enhances its market position in medical imaging, potentially driving revenue growth and attracting new research partnerships, positively impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BRKR Stock
What is Bruker Corporation's (BRKR) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Bruker Corporation (BRKR) has a median price target of $53.00. The highest price target is $69.00 and the lowest is $35.00.
Is BRKR stock a good investment in 2026?
According to current analyst ratings, BRKR has 8 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $54.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BRKR stock?
Wall Street analysts predict BRKR stock could reach $53.00 in the next 12 months. This represents a -2.3% decrease from the current price of $54.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bruker Corporation's business model?
Bruker Corporation generates revenue through the sale of scientific instruments and analytical solutions, including nuclear magnetic resonance spectrometers, mass spectrometry platforms, and imaging systems. The company also offers software, applications support, training services, and maintenance agreements, creating a comprehensive suite of offerings for its customers in various sectors.
What is the highest forecasted price for BRKR Bruker Corporation?
The highest price target for BRKR is $69.00 from at , which represents a 27.2% increase from the current price of $54.23.
What is the lowest forecasted price for BRKR Bruker Corporation?
The lowest price target for BRKR is $35.00 from at , which represents a -35.5% decrease from the current price of $54.23.
What is the overall BRKR consensus from analysts for Bruker Corporation?
The overall analyst consensus for BRKR is bullish. Out of 5 Wall Street analysts, 8 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $53.00.
How accurate are BRKR stock price projections?
Stock price projections, including those for Bruker Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 4:23 PM UTC